• 1

    JemalASiegelRXuJWardE. Cancer statistics, 2010. CA Cancer J Clin2010;60:277300.

  • 2

    KarumanchiSAMerchanJSukhatmeVP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens2002;11:3742.

    • Search Google Scholar
    • Export Citation
  • 3

    ChoykePLGlennGMWaltherMM. Hereditary renal cancers. Radiology2003;226:3346.

  • 4

    DeVitaVTJrHellmanSRosenbergSA. Cancer Principles and Practice of Oncology. 8th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

    • Search Google Scholar
    • Export Citation
  • 5

    HornerMJRiesLAKrapchoM. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2006/. Accessed June 21 2011.

    • Search Google Scholar
    • Export Citation
  • 6

    HricakHDemasBEWilliamsRD. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology1985;154:709715.

    • Search Google Scholar
    • Export Citation
  • 7

    JanusCLMendelsonDS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diagn Imaging1991;32:69118.

  • 8

    BlomJHvan PoppelHMarechalJM. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol2009;55:2834.

    • Search Google Scholar
    • Export Citation
  • 9

    BluteMLLeibovichBCChevilleJC. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol2004;172:465469.

    • Search Google Scholar
    • Export Citation
  • 10

    KuczykMMunchTMachtensS. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int2002;89:517522.

    • Search Google Scholar
    • Export Citation
  • 11

    KuczykMWegenerGJonasU. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol2005;48:252257.

    • Search Google Scholar
    • Export Citation
  • 12

    O’MalleyRLGodoyGKanofskyJATanejaSS. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol2009;181:20092017.

    • Search Google Scholar
    • Export Citation
  • 13

    HollingsworthJMMillerDCDunnRL. Surgical management of low-stage renal cell carcinoma: Technology does not supersede biology. Urology2006;67:11751180.

    • Search Google Scholar
    • Export Citation
  • 14

    LeibovichBCBluteMLChevilleJC. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol2004;171:10661070.

    • Search Google Scholar
    • Export Citation
  • 15

    ShuchBLamJSBelldegrunAS. Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep2006;7:3138.

  • 16

    ChenDYUzzoRG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw2009;7:635642; quiz 643.

    • Search Google Scholar
    • Export Citation
  • 17

    DashAVickersAJSchachterLR. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int2006;97:939945.

    • Search Google Scholar
    • Export Citation
  • 18

    LauWKBluteMLWeaverAL. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc2000;75:12361242.

    • Search Google Scholar
    • Export Citation
  • 19

    LeeCTKatzJShiW. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol2000;163:730736.

  • 20

    HuangWCLeveyASSerioAM. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol2006;7:735740.

    • Search Google Scholar
    • Export Citation
  • 21

    GoASChertowGMFanD. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med2004;351:12961305.

    • Search Google Scholar
    • Export Citation
  • 22

    WeightCJLieserGLarsonBT. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol2010;58:293298.

    • Search Google Scholar
    • Export Citation
  • 23

    WeightCJLarsonBTGaoT. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology2010;76:631637.

    • Search Google Scholar
    • Export Citation
  • 24

    FunahashiYHattoriRYamamotoT. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur Urol2009;55:209215.

    • Search Google Scholar
    • Export Citation
  • 25

    Rais-BahramiSGuzzoTJJarrettTW. Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int2009;103:13551358.

    • Search Google Scholar
    • Export Citation
  • 26

    CampbellSCNovickACBelldegrunA. Guideline for management of the clinical T1 renal mass. J Urol2009;182:12711279.

  • 27

    KunkleDAUzzoRG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer2008;113:26712680.

  • 28

    ClarkJIAtkinsMBUrbaWJ. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol2003;21:31333140.

    • Search Google Scholar
    • Export Citation
  • 29

    MessingEMManolaJWildingG. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol2003;21:12141222.

    • Search Google Scholar
    • Export Citation
  • 30

    TrumpDElsonPPropertK. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L IFN) in resected, high risk renal cell carcinoma (HR-RCC) [abstract]. Proc Am Soc Clin Oncol1996;15:Abstract 648.

    • Search Google Scholar
    • Export Citation
  • 31

    LamJSShvartsOLeppertJT. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol2005;174:466472; discussion 472; quiz 801.

    • Search Google Scholar
    • Export Citation
  • 32

    FossaSDKjolsethILundG. Radiotherapy of metastases from renal cancer. Eur Urol1982;8:340342.

  • 33

    FlaniganRCMickischGSylvesterR. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol2004;171:10711076.

    • Search Google Scholar
    • Export Citation
  • 34

    FlaniganRCSalmonSEBlumensteinBA. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med2001;345:16551659.

    • Search Google Scholar
    • Export Citation
  • 35

    MickischGHGarinAvan PoppelH. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet2001;358:966970.

    • Search Google Scholar
    • Export Citation
  • 36

    PolcariAJGorbonosAMilnerJEFlaniganRC. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Int J Urol2009;16:227233.

    • Search Google Scholar
    • Export Citation
  • 37

    CulpSHTannirNMAbelEJ. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?Cancer2010;116:33783388.

    • Search Google Scholar
    • Export Citation
  • 38

    LeibovichBCHanKRBuiMH. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer2003;98:25662575.

    • Search Google Scholar
    • Export Citation
  • 39

    RosenbergSAMuleJJSpiessPJ. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med1985;161:11691188.

    • Search Google Scholar
    • Export Citation
  • 40

    DutcherJPFisherRIWeissG. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am1997;3:157162.

    • Search Google Scholar
    • Export Citation
  • 41

    NegrierSEscudierBLassetC. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med1998;338:12721278.

    • Search Google Scholar
    • Export Citation
  • 42

    FyfeGFisherRIRosenbergSA. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol1995;13:688696.

    • Search Google Scholar
    • Export Citation
  • 43

    McDermottDFReganMMClarkJI. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol2005;23:133141.

    • Search Google Scholar
    • Export Citation
  • 44

    MotzerRJHutsonTETomczakP. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol2009;27:35843590.

    • Search Google Scholar
    • Export Citation
  • 45

    YangJCSherryRMSteinbergSM. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol2003;21:31273132.

    • Search Google Scholar
    • Export Citation
  • 46

    MotzerRJBacikJMurphyBA. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol2002;20:289296.

    • Search Google Scholar
    • Export Citation
  • 47

    LeibovichBCBluteMLChevilleJC. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer2003;97:16631671.

    • Search Google Scholar
    • Export Citation
  • 48

    MotzerRJHutsonTETomczakP. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med2007;356:115124.

  • 49

    MotzerRJMichaelsonMDRedmanBG. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol2006;24:1624.

    • Search Google Scholar
    • Export Citation
  • 50

    ChowLQEckhardtSG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol2007;25:884896.

  • 51

    FaivreSDelbaldoCVeraK. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol2006;24:2535.

    • Search Google Scholar
    • Export Citation
  • 52

    GoreMESzczylikCPortaC. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol2009;10:757763.

    • Search Google Scholar
    • Export Citation
  • 53

    EscudierBPluzanskaAKoralewskiP. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007;370:21032111.

    • Search Google Scholar
    • Export Citation
  • 54

    RiniBIChoueiriTKElsonP. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer2008;113:13091314.

  • 55

    RiniBIHalabiSRosenbergJE. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol2010;28:21372143.

    • Search Google Scholar
    • Export Citation
  • 56

    SternbergCNDavisIDMardiakJ. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol2010;28:10611068.

    • Search Google Scholar
    • Export Citation
  • 57

    HudesGCarducciMTomczakP. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med2007;356:22712281.

  • 58

    AwadaAHendliszAGilT. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer2005;92:18551861.

    • Search Google Scholar
    • Export Citation
  • 59

    ClarkJWEderJPRyanD. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res2005;11:54725480.

    • Search Google Scholar
    • Export Citation
  • 60

    MooreMHirteHWSiuL. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol2005;16:16881694.

    • Search Google Scholar
    • Export Citation
  • 61

    StrumbergDRichlyHHilgerRA. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol2005;23:965972.

    • Search Google Scholar
    • Export Citation
  • 62

    WilhelmSMCarterCTangL. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res2004;64:70997109.

    • Search Google Scholar
    • Export Citation
  • 63

    EscudierBSzczylikCHutsonTE. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol2009;27:12801289.

    • Search Google Scholar
    • Export Citation
  • 64

    MotzerRJEscudierBOudardS. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet2008;372:449456.

    • Search Google Scholar
    • Export Citation
  • 65

    MotzerRJEscudierBOudardS. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer2010;116:42564265.

    • Search Google Scholar
    • Export Citation
  • 66

    EscudierBEisenTStadlerWM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med2007;356:125134.

  • 67

    EisenTBukowskiRMStaehlerM. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 4524.

    • Search Google Scholar
    • Export Citation
  • 68

    BukowskiRMEisenTSzczylikC. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 5023.

    • Search Google Scholar
    • Export Citation
  • 69

    MotzerRJRiniBIBukowskiRM. Sunitinib in patients with metastatic renal cell carcinoma. JAMA2006;295:25162524.

  • 70

    DudekAZZolnierekJDhamA. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer2009;115:6167.

  • 71

    EichelbergCHeuerRChunFK. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol2008;54:13731378.

    • Search Google Scholar
    • Export Citation
  • 72

    HeuerREichelbergCZachariasMHeinzerH. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib [abstract]. Eur Urol Suppl2009;8:183. Abstract 251.

    • Search Google Scholar
    • Export Citation
  • 73

    SablinMPBouaitaLBalleyguierC. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients [abstract]. J Clin Oncol2007;25:Abstract 5038.

    • Search Google Scholar
    • Export Citation
  • 74

    SablinMPNegrierSRavaudA. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol2009;182:2934; discussion 34.

  • 75

    ShepardDRRiniBIGarciaJA. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract]. J Clin Oncol2008;26:Abstract 5123.

    • Search Google Scholar
    • Export Citation
  • 76

    ZimmermannKSchmittelASteinerU. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology2009;76:350354.

    • Search Google Scholar
    • Export Citation
  • 77

    DutcherJPde SouzaPMcDermottD. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol2009;26:202209.

    • Search Google Scholar
    • Export Citation
  • 78

    GordonMSHusseyMNagleRB. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol2009;27:57885793.

    • Search Google Scholar
    • Export Citation
  • 79

    DutcherJPNanusD. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncolin press.

  • 80

    NanusDMGarinoAMilowskyMI. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer2004;101:15451551.

    • Search Google Scholar
    • Export Citation
  • 81

    HaasNManolaJPinsM. ECOG 8802: phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features [abstract]. Presented at the ASCO Genitourinary Cancers Symposium 2009; February 26–28, 2009; Orlando, Florida. Abstract 285.

    • Search Google Scholar
    • Export Citation
  • 82

    LiptonAZhengMSeamanJ. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer2003;98:962969.

    • Search Google Scholar
    • Export Citation
  • 83

    RosenLSGordonDTchekmedyianNS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer2004;100:26132621.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 1 0
Full Text Views 216 216 38
PDF Downloads 37 37 6
EPUB Downloads 0 0 0